ICE Bioscience Information

ICE Bioscience was founded in 2010 as an Innovative CRO+ Explorer company. We specialize in early drug discovery services, spanning from target validation to the identification of pre-clinical candidates. Currently, ICE Bioscience offers a broad selection of off-the-shelf assays, including 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, and 40+ nuclear receptor assays, all accompanied by validation data and screening information. This comprehensive range of assays provides us with a competitive edge, as it covers a vast majority of druggable targets. Our company has established multiple platforms, encompassing Protein Engineering, Cell Line Development, Target Based Assays, Safety Pharmacology, Translational Biology, DMPK, In Vivo Pharmacology and Biophysical Assays, enabling us to smoothly execute the DMTA cycle (Design-Make-Test-Analysis cycle) for innovative drug discovery in collaboration with our clients.